Acro Biomedical (ACBM) Accumulated Expenses (2021 - 2022)

Acro Biomedical (ACBM) posted Accumulated Expenses of $19.8 million for Q1 2022, down 16.52% on a QoQ basis from $23.8 million in Q4 2021.

Analysis

Acro Biomedical (ACBM) Accumulated Expenses (2021 - 2022) Analysis & Trends

Acro Biomedical has reported Accumulated Expenses for 2 years, with the latest figure at $19.8 million in Q1 2022.

On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $19.8 million in Q1 2022; TTM through Mar 2022 was $19.8 million, a N/A change from a year earlier, with the FY2021 full-year figure at $23.8 million, changed N/A from the prior year.
Accumulated Expenses was $19.8 million for Q1 2022 at Acro Biomedical, down from $23.8 million in the prior quarter.
The five-year high for Accumulated Expenses was $23.8 million in Q4 2021, with the low at $18.5 million in Q2 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Colgate Palmolive	70.27 Bn	68.90 Bn	3.30 Bn
2	Kenvue	34.17 Bn	33.06 Bn	2.30 Bn
3	Kimberly Clark	32.86 Bn	31.91 Bn	1.60 Bn
4	Bath & Body Works	3.85 Bn	3.05 Bn	692.00 Mn
5	Prestige Consumer Healthcare	2.32 Bn	2.26 Bn	-
6	Perrigo	1.99 Bn	1.59 Bn	313.90 Mn
7	Herbalife	1.32 Bn	946.20 Mn	1.03 Bn
8	Edgewell Personal Care	1.24 Bn	842.99 Mn	242.50 Mn
9	TFA Therapeutics	1.02 Bn	1.02 Bn	-
10	Acro Biomedical	1.80 Mn	1.80 Mn	-

Historic Data

Download Data